Although further studies are needed to completely elucidate the specific molecular pathways and regulatory mechanisms involving pleiotrophin in metabolic diseases associated with altered glucose–insulin homeostasis, these findings enhance our understanding of the molecular mechanisms underlying metabolic disorders and emphasize the role of pleiotrophin as a crucial target in the endocrine pancreas for future research and therapeutic interventions. This evidence concerns the gene PTN and metabolic disease.